Stada shows strong 1st-qtr sales and earnings growth

12 May 2017

German generic drugmaker Stada Arzneimittel (SAZ: Xetra), the subject of a ~$5.6 billion takeover bid by the private equity groups Bain Capital and Cinven reports that group sales for the first-quarter 2017 increased 14% to 566.3 million euros ($615.6 million). Currency and portfolio adjusted, sales rose 8% to 538.4 million euros.

Reported operating profit for the quarter increased 36% to 76.5 million euros. The adjusted operating profit rose by 20% to 81.7 million euros. Reported earnings before interest, taxes, depreciation and amortization (EBITDA) grew by 27% to 108.6 million euros. Adjusted EBITDA recorded growth of 18% to 108.5 million euros.

“We have made a good start in the first quarter of 2017 and significantly increased both sales and all reported and adjusted key earnings figures. Thus, we are on track to reach the guidance for the current financial year,” says Dr Matthias Wiedenfels, chairman of the executive board at Stada.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK